Total costs, including pharmaceutical and healthcare costs related to propranolol treatment were greater than total costs related to corticosteroids treatment: €2,399.32 versus €1,859.68. On the other hand, the model has calculated that the cumulative QALYs associated with propranolol were equal to 19.11, while the cumulative QALYs associated with corticosteroids were equal to 18.95. Therefore, the corresponding Incremental Cost Utility Ratio (ICUR) was equal to €3,372.75 per QALY gained. The PSA analysis demonstrated that the model is robust and accurate to the variation of the inputs, as showed on the cost-effectiveness plan and on acceptability curve in Figure 2 and Figure 3 . The results suggest that 94.60% of the 1000 iterations fall within a €30,000 cost-effectiveness threshold. 
Infantile Hemangioma (IH) is one of the most common childhood benign tumors. Oral corticosteroids were considered first-line therapy of IH for long time, as indicated in national guidelines, until the publication by Léauté et al 1 showed the efficacy of propranolol in patients affected by IH. Following this discovery, recent studies, including meta-analyses and randomized clinical trials, have demonstrated the effectiveness of propranolol for involution of IH and the better clinically efficacy and safety compared to corticosteroids. The purpose of this study is to estimate the cost-utility of propranolol 3.75 mg/mL oral solution, a new medicinal product authorized for this specific paediatric indication versus corticosteroids (5.00 mg, tablets), as used in previous clinical practice in absence of other authorized therapies for proliferating IH requiring systemic treatment. 
Methods
The propranolol (3.75 mg/mL, oral solution for paediatric use) for the treatment of proliferating IH can be considered cost-effective compared to corticosteroids (5.00 mg, tablets) in the INHS perspective. Even though in Italy a cost-effectiveness threshold is not clearly defined by Institutional body, a threshold value equal to € 30,000/QALY is commonly accepted and applied in other economic evaluations. 
Conclusions

